LEADER 04227nam 22006255 450 001 9910741200703321 005 20200703024625.0 010 $a1-4614-8869-9 024 7 $a10.1007/978-1-4614-8869-9 035 $a(CKB)3710000000019064 035 $a(EBL)1466746 035 $a(SSID)ssj0001004905 035 $a(PQKBManifestationID)11636712 035 $a(PQKBTitleCode)TC0001004905 035 $a(PQKBWorkID)11046792 035 $a(PQKB)10703438 035 $a(DE-He213)978-1-4614-8869-9 035 $a(MiAaPQ)EBC1466746 035 $a(PPN)172421322 035 $a(EXLCZ)993710000000019064 100 $a20130913d2013 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aLeishmania and Leishmaniasis /$fby Awanish Kumar 205 $a1st ed. 2013. 210 1$aNew York, NY :$cSpringer New York :$cImprint: Springer,$d2013. 215 $a1 online resource (90 p.) 225 1 $aSpringerBriefs in Immunology,$x2194-2773 ;$v3 300 $aDescription based upon print version of record. 311 $a1-4614-8868-0 320 $aIncludes bibliographical references. 327 $aHistorical background of Leishmania and leishmaniasis -- Risk factors and definition of the problem -- Types of leishmaniasis -- Global status of visceral leishmaniasis -- Status of visceral leishmaniasis in India -- Morphology and Life cycle of Leishmania donovani -- Vectors and transmission of the disease -- Clinical symptoms of visceral leishmaniasis -- Control strategies of the disease -- Leishmania/HIV co-infections -- Host Immune response to Leishmania infection -- Cross-immunity between different Leishmania species -- Adoptive transfer of immunity -- Cutaneous leishmaniasis -- Mucocutaneous Leishmaniasis -- Visceral Leishmaniasis -- Post Kala-azar dermal Leishmaniasis -- Drugs against leishmaniasis -- Antimonials and Leishmaniasis -- SAG treatment, failure and resistance in Leishmania -- Vaccines against Leishmaniasis -- Strategy in practice for vaccine development against Leishmanisis. 330 $aLeishmania-related illnesses remain among the world?s deadliest neglected tropical diseases, affecting approximately 12 million people in 88 countries. The mortality rate is substantial, contributing to nearly two million disability-adjusted life years. As more is understood about this parasite and its effects, work toward prevention, control, and treatment continues apace. Leishmania and Leishmaniasis will address the parasite and its attendant disease, which manifests in three syndromes: Visceral (VL), Cutaneous (CL) and Mucocutaneous Leishmaniasis (ML). The morphology and life cycles of the various species will be among the topics addressed in Part One. Part Two will focus on immunology, including host-immune response to Leishmania infection, cross-immunity between the different species and adoptive transfer of immunity. Parts Three and Four will address how Leishmania invade and survive, the clinical features of the disease, and its diagnosis.  Drugs, vaccines and treatment will be thoroughly explored, including experimental models of therapeutics. Leishmania and Leishmaniasis will provide a thorough examination of a parasite, the illnesses it causes and the misery it continues to visit upon large segments of the population. 410 0$aSpringerBriefs in Immunology,$x2194-2773 ;$v3 606 $aImmunology 606 $aParasitology 606 $aMedicine 606 $aImmunology$3https://scigraph.springernature.com/ontologies/product-market-codes/B14000 606 $aParasitology$3https://scigraph.springernature.com/ontologies/product-market-codes/B19002 606 $aBiomedicine, general$3https://scigraph.springernature.com/ontologies/product-market-codes/B0000X 615 0$aImmunology. 615 0$aParasitology. 615 0$aMedicine. 615 14$aImmunology. 615 24$aParasitology. 615 24$aBiomedicine, general. 676 $a610 700 $aKumar$b Awanish$4aut$4http://id.loc.gov/vocabulary/relators/aut$01424757 906 $aBOOK 912 $a9910741200703321 996 $aLeishmania and Leishmaniasis$93554253 997 $aUNINA LEADER 00807nam 2200265 450 001 996689977303316 005 20251203152344.0 100 $a20251203d1967----km y0itay5003 ba 101 0 $aita 102 $aIT 105 $ay 00 y 200 1 $aSulle società operanti in più ordinamenti$fEduardo Spano 210 $aMilano$cGiuffrè$d[1967] 215 $a[1290]-1299 p.$d25 cm 300 $aEstratto da: Rivista delle società, anno 12, fasc. 6 (nov.-dic. 1967) 606 0 $aSocietà $2BNCF 676 $a338.7 700 1$aSPANO,$bEduardo$01858150 801 0$aIT$bcba$gREICAT 912 $a996689977303316 951 $aXVI.7.Misc. 784$b791 FBUO$cXVI.7.Misc. 959 $aBK 969 $aFBUO 996 $aSulle società operanti in più ordinamenti$94459740 997 $aUNISA